In recent years, it has emerged as the preferred method for staging newly diagnosed high-risk prostate cancer, finding sites of recurrence and evaluating eligibility for treatment with [177Lu]Lu-PSMA-617 and analogues [8–10]. Here, FOLH1 is linked to prostate cancer.